In a nutshell This phase 2 trial will investigate the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer (NSCLC). The main outcomes will be the number of treatment-related adverse events (TRAEs) and progression-free survival (PFS). The details Non-small cell lung cancer (NSCLC)...
Read MoreTreatment(s) already received-Chemotherapy Posts on Medivizor
PET scans in determining outcomes for patients with Hodgkin lymphoma treated with chemotherapy
In a nutshell This study aimed to investigate the role of positron emission tomography (PET; an imaging technique) in determining the outcomes for patients with Hodgkin lymphoma treated with chemotherapy. This study concluded that negative-PET scans after chemotherapy predict good outcomes for these patients, regardless of stage at...
Read MoreEvaluating palbociclib for patients with previously treated breast cancer
In a nutshell This study evaluated how well palbociclib (Ibrance) works in patients with breast cancer who received multiple lines of previous therapy. This study found that palbociclib was effective for these patients. Some background There are several different treatments for breast cancer depending on the types of...
Read MoreSearching for patients with non-small cell lung cancer to trial a new targeted therapy drug
In a nutshell This phase 3 trial will investigate the safety and effectiveness of osimertinib (Tagrisso) after chemoradiation (CR) in non-small cell lung cancer (NSCLC). The main outcome will be progression-free survival (PFS; survival without cancer growing or spreading). The details Non-small cell lung cancer (NSCLC) is the most...
Read MoreThe frequency of advanced colorectal neoplasia in Hodgkin lymphoma survivors
In a nutshell This study aimed to investigate the frequency of advanced colorectal neoplasia (ACN; abnormal growth of tissue in the bowel) in Hodgkin lymphoma (HL) survivors. This study concluded that HL survivors treated with abdominal radiotherapy and/or alkylating chemotherapy have a high frequency of ACN. Some background...
Read MoreSearching for patients to try a new combination of treatments for relapsed or unresponsive Hodgkin lymphoma.
In a nutshell This study will investigate the effects of pembrolizumab (Keytruda) and targeted radiation therapy for relapsed or unresponsive Hodgkin lymphoma (HL). This study will measure the rate of complete response (disappearance of all cancer). The details Many patients are cured with treatments for HL. Some patients lose response to...
Read MoreLooking for patients advanced colorectal cancer to test a new treatment and a predictive blood test
In a nutshell This trial is examining the effectiveness of circulating cell-free tumor DNA (cCFTD) as a predictive factor for the treatment of advanced colorectal cancer with regorafenib (Stivarga) or TAS-102. The main outcome to be measured will be to evaluate the ability of early change of cCFTD after the start of the treatment. This trial will be...
Read MoreConsolidation chemotherapy before surgery improves the outcomes in advanced rectal cancer.
In a nutshell This study investigated the effectiveness and safety of consolidation chemotherapy after initial treatment in locally advanced rectal cancer. Researchers suggested that this treatment is safe and is associated with improved cancer outcomes. Some background Colorectal cancer is the fifth most common cancer. From all the colorectal...
Read MoreThe use of brentuximab vedotin before transplant for patients with Hodgkin’s lymphoma
In a nutshell This study aimed to compare outcomes for patients with Hodgkin’s lymphoma who received brentuximab vedotin (Adcetris) compared to chemotherapy before a stem cell transplant. This study concluded that patients who received brentuximab vedotin had a better survival. Some background Allogeneic hematopoietic stem cell...
Read MoreLooking for participants to test the effectiveness and safety of vicriviroc in the treatment of advanced colorectal cancer
In a nutshell This trial is examining the effectiveness and safety of vicriviroc (VIC) plus pembrolizumab (Keytruda) in the treatment of advanced colorectal cancer. The main outcome to be measured is the tumor response to treatment. This trial is being conducted in the US and Canada. The details Colorectal cancer is the third most common...
Read MoreLooking for patients with relapsed or refractory lymphoma to test a cell therapy
In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...
Read MoreLooking for men with castration-resistant prostate cancer to try 177Lu-PSMA-617
In a nutshell This trial is looking at the effectiveness of 177Lu-PSMA-617 in the treatment of castration-resistant (tumor grows even with hormone therapy) prostate cancer. The main outcome to be measured is overall survival. The details Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate...
Read More
